000K  utf8
1100  $c2011
1500  eng
2050  urn:nbn:de:gbv:8-diss-61619
3000  Mohseni Nodehi, Sahar
4000  Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96$hChristian-Albrechts-Universität zu Kiel  [Mohseni Nodehi, Sahar]
4030  Kiel$nChristian-Albrechts-Universität zu Kiel
4209  Regardless of progress in the therapy of AML, there is no long-term cure for about 70% of AML patients. Leukemic stem cells seem to be an important key for the perpetuation of AML.Most currently used chemotherapeutic agents are not able to eliminate AML-LSCs. The combination of conventional therapies with AML-LSCs-directed therapies may eventually lead to a cure for AML patients.Recently expression of CD96 was reported on AML-LSCs, while only very low expression levels were found on normal HSCs.Therefore CD96 may be an excellent target antigen for therapeutic antibodies directed against AML stem cells and blasts.
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8-diss-61619$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/diss_mods_00006161
5051  500
5550  ADCC
5550  affinity maturation
5550  AML-LSC
5550  antibody-engineering
5550  CD96